Safety issues with glucagon‐like peptide‐1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): <scp>D</scp> ata from randomized controlled trials

Matteo Monami, Edoardo Mannucci, Alessia Scatena et al.|Diabetes Obesity and Metabolism|2017

Cited by 226